- Home
- PAXS vs KOD Comparison
PAXS vs KOD Comparison
Compare PAXS & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- KOD
- Stock Information
- Founded
- PAXS 2021
- KOD 2009
- Country
- PAXS United States
- KOD United States
- Employees
- PAXS N/A
- KOD N/A
- Industry
- PAXS Investment Managers
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAXS Finance
- KOD Health Care
- Exchange
- PAXS Nasdaq
- KOD Nasdaq
- Market Cap
- PAXS 734.1M
- KOD 795.5M
- IPO Year
- PAXS N/A
- KOD 2018
- Fundamental
- Price
- PAXS N/A
- KOD $12.48
- Analyst Decision
- PAXS
- KOD Buy
- Analyst Count
- PAXS 0
- KOD 6
- Target Price
- PAXS N/A
- KOD $14.33
- AVG Volume (30 Days)
- PAXS 195.0K
- KOD 1.1M
- Earning Date
- PAXS 01-01-0001
- KOD 11-13-2025
- Dividend Yield
- PAXS 11.72%
- KOD N/A
- EPS Growth
- PAXS N/A
- KOD N/A
- EPS
- PAXS N/A
- KOD N/A
- Revenue
- PAXS N/A
- KOD N/A
- Revenue This Year
- PAXS N/A
- KOD N/A
- Revenue Next Year
- PAXS N/A
- KOD N/A
- P/E Ratio
- PAXS N/A
- KOD N/A
- Revenue Growth
- PAXS N/A
- KOD N/A
- 52 Week Low
- PAXS $12.57
- KOD $1.92
- 52 Week High
- PAXS $15.93
- KOD $19.39
- Technical
- Relative Strength Index (RSI)
- PAXS 49.19
- KOD 48.85
- Support Level
- PAXS $16.23
- KOD $11.42
- Resistance Level
- PAXS $16.56
- KOD $15.01
- Average True Range (ATR)
- PAXS 0.14
- KOD 1.72
- MACD
- PAXS -0.03
- KOD -0.51
- Stochastic Oscillator
- PAXS 32.76
- KOD 17.51
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.